An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Clinical trial NCT06480552 · RECRUITING
Trial details
- NCT number
- NCT06480552
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-22
- Primary completion
- 2029-05-26
- Enrollment
- 240
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.